The effect of CFH polymorphisms on the response to the treatment of age-related macular degeneration (AMD) with intravitreal ranibizumab

Molecular Vision

Volumn 19, Issue , 2013, Pages 2571-2578

  Dikmetas, Ozlem ^a   Kadayifcilar, Sibel ^a   Eldem, Bora ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT FACTOR H; RANIBIZUMAB;

ADULT; AGED; ARTICLE; CENTRAL MACULAR THICKNESS; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; FOLLOW UP; GENETIC ANALYSIS; GENOTYPE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OCULAR FIBROSIS; PATIENT MONITORING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION; VERY ELDERLY; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ALLELES; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL MARKERS; CHOROIDAL NEOVASCULARIZATION; COMPLEMENT FACTOR H; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; MIDDLE AGED; NUCLEIC ACID DENATURATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84890891018     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Ngai LY, Stocks N, Sparrow JM, Patel R, Rumley A, LoweG, Smith GD, Ben-Shlomo Y. The prevalence and analysis of risk factors for age-related macular degeneration: 18-year follow-up data from the Speedwell eye study, United Kingdom. Eye (Lond) 2011; 25:784-793.[PMID: 21436849].
2. Swaroop A, Chew EY, Rickman CB, Abecasis GR. Unraveling a Multifactorial Late-Onset Disease: From Genetic Susceptibility to Disease Mechanisms for Age-Related Macular Degeneration. Annu Rev Genomics Hum Genet 2009; 10:19-43.[PMID: 19405847].
3. Friedman DS, O'Colmain BJ, Muñoz B, Tomany SC, McCarty C, de Jong PT, Nemesure B, Mitchell P, Kempen J. Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004; 122:564-72.[PMID: 15078675].
4. Wong TY, Chakravarthy U, Klein R, Mitchell P, Zlateva G, Buggage R, Fahrbach K, Probst C, Sledge I. The natural history and prognosis of neovascular age-related macular degeneration a systematic review of the literature and meta-analysis. Ophthalmology 2008; 115:116-26.[PMID: 176 75159].
5. Klein R. Race/ethnicity and age-related macular degeneration. Am J Ophthalmol 2011; 152:153-4.[PMID: 21784191].
6. Leveziel N, Tilleul J, Puche N, Zerbib J, Laloum F, Querques G, Souied EH. Genetic factors associated with age-related macular degeneration. Ophthalmologica 2011; 226:87-102.[PMID: 217578 76].
7. Kloeckener-Gruissem B, Barthelmes D, Labs S, Schindler C, Kurz-Levin M, Michels S, Fleischhauer J, Berger W, Sutter F, Menghini M. Genetic association with response to intravit-real ranibizumab in patients with neovascular AMD. Invest Ophthalmol Vis Sci 2011; 52:4694-702.[PMID: 21282580].
8. Klaver CC, Wolfs RC, Assink JJ, van Duijn CM, Hofman A, de Jong PT. Genetic risk of age-related maculopathy. Population-based familial aggregation study. Arch Ophthalmol 1998; 116:1646-51.[PMID: 9869796].
9. Machalińska A, Kawa MP, Marlicz W, Machaliński B. Complement system activation and endothelial dysfunction in patients with age-related macular degeneration (AMD): possible relationship between AMD and atherosclerosis. Acta Ophthalmol (Copenh) 2012; 90:695-703.[PMID: 22067048].
10. Schwartz SG, Brantley M. Pharmacogenetics and age-related macular degeneration. J Ophthalmol 2011; 2011:252549[PMID: 22046503].
11. Gotoh N, Yamada R, Hiratani H, Renault V, Kuroiwa S, Monet M, Toyoda S, Chida S, Mandai M, Otani A, Yoshimura N, Matsuda F. No association between complement factor H gene polymorphism and exudative age-related macular degeneration in Japanese. Hum Genet 2006; 120:139-43.[PMID: 16710702].
12. Loyet KM, Deforge LE, Katschke KJ Jr, Diehl L, Graham RR, Pao L, Sturgeon L, Lewin-Koh SC, Hollyfield JG, van Look-eren Campagne M. Activation of the alternative complement pathway in vitreous is controlled by genetics in age-related macular degeneration. Invest Ophthalmol Vis Sci 2012; 53:6628[PMID: 22930722].
13. Mello E, Falsini B, Zuppi C, Giardino B, Concolino P, Capo-luongo E. Rapid detection of CFH (p.Y402H) and ARMS2 (p.A69S) polymorphisms in age-related macular degeneration using high-resolution melting analysis. Clin Chem Lab Med 2012; 50:1031-4.[PMID: 22706242].
14. Pushpoth S, Sykakis E, Merchant K, Browning AC, Gupta R, Talks SJ. Measuring the benefit of 4 years of intravitreal ranibizumab treatment for neovascular age-related macular degeneration. Br J Ophthalmol 2012; 96:1469-73.[PMID: 23001255].
15. Kaiser PK, Brown DM, Zhang K. ve ark. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol 2007; 144:850-7.[PMID: 17949673].
16. Boyer DS, Antoszyk AN, Awh CC. ve ark. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmol. 2007; 114:246-52.
17. Lommatzsch A. Pigment epithelial detachment in exudative macular degeneration: clinical characteristics and therapeutic options. Ophthalmologe 2010; 107:1115-22.[PMID: 2115 35 76].
18. Lee SJ, Koh HJ. Effects of vitreomacular adhesion on anti-vascular endothelial growth factor treatment for exudative age-related macular degeneration. Ophthalmol. 2011; 118: 101-110.[PMID: 20678805].
19. Souied EH, Leveziel N, Richard F. Y402H Complement factor H polymorphism associated with exudative age-related macular degeneration in the French population. Mol Vis 2005; 11:1135-1140.[PMID: 16379025].
20. Soysal Y, Inan UU, Küsbeci T, Imirzalioǧlu N. Age-related macular degeneration and association of CFH Y402H and LOC387715 A69S polymorphisms in a Turkish population. DNA Cell Biol 2012; 31:323-30.[PMID: 2179 0300].
21. Seitsonen S, Jarvela I, Meri S, Tommila P, Ranta P, Immonen I. Complement factor H Y402H polymorphism and characteristics of exudative age-related macular degeneration lesions. Acta Ophthalmol (Copenh) 2008; 86:390-4.[PMID: 17995985].
22. Seitsonen SP, Jarvela IE, Meri S, Tommila P, Ranta P, Immonen I. The effect of complement factor H Y402H polymorphism on the outcome of photodynamic therapy in age-related macular degeneration. Eur J Ophthalmol 2007; 17:943-9.[PMID: 18 050121].
23. Teper SJ, Nowinska A, Pilat J, Palucha A, Wylegala E. Involment of genetic factors in the response to a varible dosing ranibizumab treatment regimen for age related macular degeneration. Mol Vis 2010; 16:2598-604. [PMID: 21151600].
24. McKibbin M, Ali M, Bansal S, Baxter PD, West K, Williams G, Cassidy F, Inglehearn CF. CFH, VEGF and HTRA1 promoter genotype may influence the response to intravitreal ranibizumab therapy for neovascular age-related macular degeneration. Br J Ophthalmol 2012; 96:208-12.[PMID: 21558292].
25. Brantley MA, Osborn MP, Sanders BJ, Rezaei KA, Lu P, Li C, Milne GL, Cai J, Sternberg P Jr. Plasma biomarkers of oxidative stress and genetic variants in age-related macular degeneration. Am J Ophthalmol 2012; 153:460-7.[PMID: 22035603].
26. Kloeckener-Gruissem B, Barthelmes D, Labs S. Genetic association with response to intravitreal ranibizumab in patients with neovascular AMD. Invest Ophthalmol Vis Sci 2011; 52:4694-702.[PMID: 21282580].
27. Lee AY, Raya A K, Ky mes SM, Shiels A, Brantley MA Jr. Phar-macogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibi-zumab. Br J Ophthalmol 2009; 93:610-3.[PMID: 19091853].
28. Micieli JA. Can genetic factors predict response to antivascular endothelial growth factor therapy in age-related macular degeneration? Can J Ophthalmol 2011; 46:549-51.[PMID: 22153646].
29. Abedi F, Wickremasinghe S, Richardson AJ, Islam A F, Guymer RH, Baird PN. Genetic Influences on the Outcome of Anti-Vascular Endothelial Growth Factor Treatment in Neovas-cular Age-related Macular Degeneration. Ophthalmol. 2013; 120:1641-8.[PMID: 2 358 29 91].